{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:33:16Z","timestamp":1791160396751,"version":"4.1.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2016-00875"],"award-info":[{"award-number":["2016-00875"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003173","name":"Crafoord Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0235021","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T17:38:17Z","timestamp":1593020297000},"page":"e0235021","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-9796","authenticated-orcid":true,"given":"Shai","family":"Mulinari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-8182","authenticated-orcid":true,"given":"Andreas","family":"Vilhelmsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ozieranski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"pone.0235021.ref001","doi-asserted-by":"crossref","DOI":"10.4337\/9780857931818","volume-title":"Democratizing health: Consumer groups in the policy process","author":"H L\u00f6fgren","year":"2011"},{"key":"pone.0235021.ref002","doi-asserted-by":"crossref","DOI":"10.4324\/9781315741871","volume-title":"The public shaping of medical research: patient associations, health movements and biomedicine","author":"P Wehling","year":"2014"},{"issue":"1","key":"pone.0235021.ref003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/erp.10.82","article-title":"Role of patient and public participation in health technology assessment and coverage decisions.","volume":"11","author":"D Menon","year":"2011","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"pone.0235021.ref004","doi-asserted-by":"crossref","first-page":"k5300","DOI":"10.1136\/bmj.k5300","article-title":"Financial interests of patient organisations contributing to technology assessment at England\u2019s National Institute for Health and Care Excellence: policy review","volume":"364","author":"KL Mandeville","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"pone.0235021.ref005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1369-7625.2007.00472.x","article-title":"Health consumer and patients' organizations in Europe: towards a comparative analysis.","volume":"11","author":"R Baggott","year":"2008","journal-title":"Health Expect"},{"issue":"7600","key":"pone.0235021.ref006","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/bmj.39185.461968.AD","article-title":"Should patient groups accept money from drug companies?","volume":"334","author":"A Kent","year":"2007","journal-title":"Yes. BMJ"},{"key":"pone.0235021.ref007","doi-asserted-by":"crossref","first-page":"j1251","DOI":"10.1136\/bmj.j1251","article-title":"Industry links with patient organisations","volume":"356","author":"J Taylor","year":"2017","journal-title":"BMJ"},{"key":"pone.0235021.ref008","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fmed.2018.00230","article-title":"EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes","volume":"5","author":"D Haerry","year":"2018","journal-title":"Front Med"},{"issue":"2","key":"pone.0235021.ref009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/11589210-000000000-00000","article-title":"Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.","volume":"5","author":"SL di Priolo","year":"2012","journal-title":"Patient"},{"key":"pone.0235021.ref010","doi-asserted-by":"crossref","first-page":"l740","DOI":"10.1136\/bmj.l740","article-title":"ABPI guidance on drug companies and patient organisations","volume":"364","author":"J Pearcy","year":"2019","journal-title":"BMJ"},{"key":"pone.0235021.ref011","doi-asserted-by":"crossref","first-page":"l6694","DOI":"10.1136\/bmj.l6694","article-title":"\u201cAsset exchange\u201d-interactions between patient groups and pharmaceutical industry: Australian qualitative study.","volume":"367","author":"L Parker","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"pone.0235021.ref012","doi-asserted-by":"crossref","first-page":"e0212399","DOI":"10.1371\/journal.pone.0212399","article-title":"Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.","volume":"14","author":"J Lexchin","year":"2019","journal-title":"PLOS ONE"},{"issue":"9","key":"pone.0235021.ref013","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1056\/NEJMsr1610625","article-title":"Conflicts of interest for patient-advocacy organizations.","volume":"376","author":"MS McCoy","year":"2017","journal-title":"NEJM"},{"issue":"3","key":"pone.0235021.ref014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamainternmed.2016.8443","article-title":"Patient advocacy organizations, industry funding, and conflicts of interest","volume":"177","author":"SL Rose","year":"2017","journal-title":"JAMA Internal Med"},{"key":"pone.0235021.ref015","doi-asserted-by":"crossref","unstructured":"Batt S. Health Advocacy, Inc.: How Pharmaceutical Funding Changed the Breast Cancer Movement: UBC Press; 2017.","DOI":"10.59962\/9780774833868"},{"issue":"4","key":"pone.0235021.ref016","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1071\/AH17288","article-title":"How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.","volume":"43","author":"E Lau","year":"2018","journal-title":"Austral Health Rev"},{"issue":"4","key":"pone.0235021.ref017","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jamadermatol.2018.5102","article-title":"Prevalence and disclosure of potential conflicts of interest in dermatology patient advocacy prganizations","volume":"155","author":"DG Li","year":"2019","journal-title":"JAMA Dermatology"},{"key":"pone.0235021.ref018","article-title":"The patient and consumer voice and pharmaceutical industry sponsorship.","author":"SK Perehudoff","year":"2011","journal-title":"Amsterdam: HAI Europe."},{"key":"pone.0235021.ref019","doi-asserted-by":"crossref","DOI":"10.1057\/9781137349477","volume-title":"Unhealthy pharmaceutical regulation: Innovation, politics and promissory science","author":"C Davis","year":"2013"},{"issue":"2","key":"pone.0235021.ref020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1057\/jphp.2016.6","article-title":"Unhealthy marketing of pharmaceutical products: An international public health concern.","volume":"37","author":"S Mulinari","year":"2016","journal-title":"J Pub Health Policy"},{"issue":"5","key":"pone.0235021.ref021","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1467-9566.2012.01528.x","article-title":"Regulating drug information in Europe: a pyrrhic victory for pharmaceutical industry critics?","volume":"35","author":"S Mulinari","year":"2013","journal-title":"Sociol Health Illn."},{"issue":"12","key":"pone.0235021.ref022","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.healthpol.2019.08.007","article-title":"Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.","volume":"123","author":"E Rickard","year":"2019","journal-title":"Health Policy."},{"issue":"6","key":"pone.0235021.ref023","doi-asserted-by":"crossref","first-page":"504","DOI":"10.15171\/ijhpm.2018.20","article-title":"Sunshine policies and murky shadows in Europe: disclosure of pharmaceutical industry payments to health professionals in nine European countries.","volume":"7","author":"A Fabbri","year":"2018","journal-title":"Int J Health Policy Manag"},{"issue":"5","key":"pone.0235021.ref024","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.healthpol.2018.03.015","article-title":"Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia.","volume":"122","author":"Q Grundy","year":"2018","journal-title":"Health Policy"},{"key":"pone.0235021.ref025","unstructured":"EFPIA. EFPIA Code of Practice on relationships between the pharmaceutical industry and Patient Organisations. 2011. https:\/\/www.efpia.eu\/media\/24310\/3c_efpia-code-of-practice-on-relationships-pharmapluspt-orgs.pdf Accessed 30 Dec 2019."},{"key":"pone.0235021.ref026","doi-asserted-by":"crossref","first-page":"l1806","DOI":"10.1136\/bmj.l1806","article-title":"Exposing drug industry funding of UK patient organisations.","volume":"365","author":"P Ozieranski","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"pone.0235021.ref027","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0020731418823376","article-title":"Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis.","volume":"49","author":"A Fabbri","year":"2019","journal-title":"Inter J Health Serv."},{"issue":"4","key":"pone.0235021.ref028","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2105\/AJPH.2018.304946","article-title":"Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.","volume":"109","author":"SY Kang","year":"2019","journal-title":"Am J Pub Health."},{"issue":"8","key":"pone.0235021.ref029","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.socscimed.2010.01.005","article-title":"Co-operation between patient organisations and the drug industry in Finland.","volume":"70","author":"E Hemminki","year":"2010","journal-title":"Soc Sci Med"},{"issue":"1","key":"pone.0235021.ref030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1471-2458-6-201","article-title":"Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.","volume":"6","author":"DE Ball","year":"2006","journal-title":"BMC Public Health"},{"issue":"4","key":"pone.0235021.ref031","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2105\/AJPH.2010.300027","article-title":"Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.","volume":"101","author":"SM Rothman","year":"2011","journal-title":"Am J Pub Health"},{"issue":"2","key":"pone.0235021.ref032","doi-asserted-by":"crossref","first-page":"e1001785","DOI":"10.1371\/journal.pmed.1001785","article-title":"Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004\u20132012: A quantitative and qualitative study of pharmaceutical Industry self-regulation.","volume":"12","author":"AV Zetterqvist","year":"2015","journal-title":"PLoS Med"},{"key":"pone.0235021.ref033","unstructured":"Myndigheten f\u00f6r V\u00e5rdanalys. Sjukt engagerad\u2014en kartl\u00e4ggning av patient-och funktionshinderr\u00f6relsen (Rapport 2015: 4). Stockholm; 2015. https:\/\/www.vardanalys.se\/rapporter\/sjukt-engagerad\/. Accessed 30 Dec 2019."},{"key":"pone.0235021.ref034","unstructured":"LIF. Samarbetsdatabaser. https:\/\/www.lif.se\/etik\/samarbetsdatabaser\/ Accessed 30 Dec 2019."},{"issue":"11","key":"pone.0235021.ref035","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.mayocp.2016.08.015","article-title":"Industry funding of cancer patient advocacy organizations","volume":"91","author":"MV Abola","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"pone.0235021.ref036","doi-asserted-by":"crossref","first-page":"e34974","DOI":"10.1371\/journal.pone.0034974","article-title":"Patient organizations\u2019 funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.","volume":"7","author":"C Colombo","year":"2012","journal-title":"PLoS One."},{"issue":"1","key":"pone.0235021.ref037","first-page":"52","article-title":"Coalition Priorit\u00e9 Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?","volume":"9","author":"D Hughes","year":"2013","journal-title":"Healthc Policy."},{"issue":"10","key":"pone.0235021.ref038","doi-asserted-by":"crossref","first-page":"e023094","DOI":"10.1136\/bmjopen-2018-023094","article-title":"Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry\u2019s Disclosure UK database, 2015 and 2016 cohorts","volume":"8","author":"S Mulinari","year":"2018","journal-title":"BMJ Open"},{"issue":"6","key":"pone.0235021.ref039","doi-asserted-by":"crossref","first-page":"e196253","DOI":"10.1001\/jamanetworkopen.2019.6253","article-title":"Analysis of pharmaceutical industry payments to UK healthcare organizations in 2015","volume":"2","author":"P Ozieranski","year":"2019","journal-title":"JAMA Netw Open"},{"key":"pone.0235021.ref040","unstructured":"Institute for Health Metrics and Evaluation (IHME). Sweden profile. 2018. http:\/\/www.healthdata.org\/sweden. Accessed 30 Dec 2019."},{"key":"pone.0235021.ref041","unstructured":"Institute for Health Metrics and Evaluation (IHME). Global Health Data Exchange. GBD 2017 data. https:\/\/vizhub.healthdata.org\/gbd-compare\/ Accessed 30 Dec 2019."},{"issue":"11","key":"pone.0235021.ref042","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jamaoncol.2018.4300","article-title":"Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration based on single-arm trials","volume":"4","author":"A Tibau","year":"2018","journal-title":"JAMA Oncol"},{"key":"pone.0235021.ref043","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009\u201313","volume":"359","author":"C Davis","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"pone.0235021.ref044","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"V Prasad","year":"2015","journal-title":"JAMA Internal Med"},{"key":"pone.0235021.ref045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.socscimed.2014.11.003","article-title":"Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.","volume":"124","author":"A Ferrario","year":"2015","journal-title":"Soc Sci Med"},{"key":"pone.0235021.ref046","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.socscimed.2018.12.025","article-title":"Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union.","volume":"222","author":"J Hoekman","year":"2019","journal-title":"Soc Sci Med"},{"key":"pone.0235021.ref047","article-title":"Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab.","author":"C Pontes","year":"2019","journal-title":"Appl Health Econ Health Policy."},{"key":"pone.0235021.ref048","doi-asserted-by":"crossref","first-page":"l5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014\u201316: cross sectional analysis","volume":"366","author":"H Naci","year":"2019","journal-title":"BMJ"},{"key":"pone.0235021.ref049","unstructured":"LIF. 2020. Ethical Rules for the Pharmaceutcial Industry in Sweden. https:\/\/www.lif.se\/globalassets\/etik\/dokument\/ler-english-version-2020-0501-jd-24apr-pdf.pdf. Accessed 2 June 2020."},{"key":"pone.0235021.ref050","volume-title":"Regulating medicines in Europe: competition, expertise and public health.","author":"J Abraham","year":"2000"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T22:08:43Z","timestamp":1696284523000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235021"}},"subtitle":[],"editor":[{"given":"Joel","family":"Lexchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0235021","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}